European Reimbursement Model Could Spur Drug Innovation – FasterCures
Executive Summary
Providing higher reimbursement for first-in-class drugs is one way to boost innovation in the U.S., FasterCures says in comments to HHS
You may also be interested in...
FDA Should Consider Raising Evidence Standards For Approval, Blues Say
FDA should consider bringing evidence requirements for drug applications in line with Medicare's coverage decision standard, Blue Cross Blue Shield Association suggested in comments to HHS
FDA Should Consider Raising Evidence Standards For Approval, Blues Say
FDA should consider bringing evidence requirements for drug applications in line with Medicare's coverage decision standard, Blue Cross Blue Shield Association suggested in comments to HHS
Merck Defends Right Not To Publish Clinical Trials
Merck believes clinical trial disclosure rules must distinguish between hypothesis-generating and hypothesis-testing trials